The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Rapaflo     1-(3-hydroxypropyl)-5-[(2R)- 2-[2-[2-(2,2,2...

Synonyms: Silodosin, Silodyx, Rapflo, Urorec, Urief, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Silodosin


High impact information on Silodosin


Chemical compound and disease context of Silodosin


Biological context of Silodosin

  • In the present study, we investigated the effects of KMD-3213 on the tilt-induced blood pressure response in anesthetized normotensive rats [2].

Anatomical context of Silodosin


Associations of Silodosin with other chemical compounds

  • [3H]-PZ binding sites consisted of low- and high-affinity sites for KMD-3213 (pKi = 7.6 and 10.7, respectively), for WB4101 (pK = 8.1 and 10.0) and for YM-617 (pKi = 8.7 and 10.8) [12].

Gene context of Silodosin

  • Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta [9].

Analytical, diagnostic and therapeutic context of Silodosin


  1. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. Tatemichi, S., Akiyama, K., Kobayashi, M., Yamazaki, Y., Yokoyama, O., Uruno, T. J. Urol. (2006) [Pubmed]
  2. Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats. Akiyama, K., Hora, M., Yamagishi, R., Kitazawa, M. Jpn. J. Pharmacol. (2002) [Pubmed]
  3. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Shibata, K., Foglar, R., Horie, K., Obika, K., Sakamoto, A., Ogawa, S., Tsujimoto, G. Mol. Pharmacol. (1995) [Pubmed]
  4. Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. Morishima, S., Tanaka, T., Yamamoto, H., Suzuki, F., Akino, H., Yokoyama, O., Muramatsu, I. J. Urol. (2007) [Pubmed]
  5. Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats. Zhang, L., Taniguchi, T., Tanaka, T., Shinozuka, K., Kunitomo, M., Nishiyama, M., Kamata, K., Muramatsu, I. Br. J. Pharmacol. (2002) [Pubmed]
  6. Silodosin, a new alpha-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. Kawabe, K., Yoshida, M., Homma, Y. BJU Int. (2006) [Pubmed]
  7. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. Murata, S., Taniguchi, T., Takahashi, M., Okada, K., Akiyama, K., Muramatsu, I. J. Urol. (2000) [Pubmed]
  8. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Tatemichi, S., Tomiyama, Y., Maruyama, I., Kobayashi, S., Kobayashi, K., Maezawa, A., Kobayashi, M., Yamazaki, Y., Shibata, N. Neurourol. Urodyn. (2006) [Pubmed]
  9. Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Yamagishi, R., Akiyama, K., Nakamura, S., Hora, M., Masuda, N., Matsuzawa, A., Murata, S., Ujiie, A., Kurashina, Y., Iizuka, K., Kitazawa, M. Eur. J. Pharmacol. (1996) [Pubmed]
  10. In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia. Yamada, S., Ohkura, T., Kimura, R., Kawabe, K. Life Sci. (1998) [Pubmed]
  11. Selective and sustained occupancy of prostatic alpha1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats. Okura, T., Yamada, S., Abe, Y., Kimura, R. J. Pharm. Pharmacol. (2002) [Pubmed]
  12. Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand. Murata, S., Taniguchi, T., Muramatsu, I. Br. J. Pharmacol. (1999) [Pubmed]
  13. Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Sugawara, T., Hirasawa, A., Hashimoto, K., Tsujimoto, G. Life Sci. (2002) [Pubmed]
WikiGenes - Universities